New Therapies Provide Options in Metastatic Breast CancerNovember 28th 2020
Comparing the efficacy of selective HER2 kinase inhibitors in HER2-positive metastatic breast cancer, it was shown that tucatinib may have been approved in the second-line setting due to it's unique impact on the central nervous system. Another HER2 inhibitor, trastuzumab deruxtecan has demonstrated promise in a phase 2 study and is now being confirmed in a phase 3 study.
In Patients With NSCLC Relapsing Shortly After Frontline Therapy Initiation, Ramucirumab Combination ImpressesNovember 27th 2020
During a Targeted Oncology Case Based Peer Perspectives event, Antoinette Wozniak, MD, discussed the case of a 59-year-old man with non-small cell lung cancer.
Exploring First-line Therapies in Peripheral T-Cell LymphomasNovember 23rd 2020
During the Targeted Oncology Case Based Peer Perspectives event, Javier L. Munoz, MD, Hematologist/Oncologist Director, Lymphoma Program Mayo Clinic, discussed the case of 60-year-old patient with peripheral T-cell lymphoma.
Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLCNovember 21st 2020
During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.
Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC Is Standard of Care for Most OncologistsNovember 16th 2020
During a Targeted Oncology Case Based Peer Perspective event, Corey J. Langer, MD, discussed options for a 63-year-old patient with stage III non–small cell lung cancer.